China Pharma Holdings Inc. (CPHI): Price to Sales

China Pharma Holdings (CPHI) maintains its position as a leader in China's generics market, leveraging government procurement of affordable medications. The company's price/sales multiple reflects current valuation trends, where 5.20 marks a new level. However, a lack of R&D innovation is constraining growth. Business stability is underpinned by strict licensing and an extensive distribution network across provincial pharmacies.
Metric breakdowns and analytics for China Pharma (CPHI)

The market valuation of China Pharma Holdings (CPHI) relative to its operating income allows investors to determine the fair scale of the business amid sector volatility. By analyzing P/S levels on this chart, where market capitalization is divided by annual revenue, one can assess the efficiency of the diversified generics portfolio, which mitigates government pricing regulation risks and stabilizes the company's fundamental value.